Updated:
Sinobioway Medicine
Sinobioway Medicine invests globally in life sciences and digital health, operating from offices in West Palm Beach, Xiamen, and Shanghai.
Sinobioway Medicine
Sinobioway Medicine was founded in 2005 to bridge Chinese and Western healthcare innovation. The firm operates as a multi-family office and asset manager, with roots in the pharmaceutical sector. The firm invests across digital health, biotechnology, pharmaceuticals, and agritech. Its stage coverage ranges from series A to growth equity, with direct deals and co-investments alongside institutional partners. Portfolio companies span precision medicine, diagnostics, and telemedicine platforms. The team includes investment professionals in the US and China. AUM is estimated between $500M and $1B based on public filings and deal history (Altss estimate). The firm maintains separate philanthropic vehicles focused on global health access. The firm differentiates itself through a dual-region sourcing model — originating deals in both North America and Asia. Its Chinese offices provide on-the-ground access to manufacturing and regulatory pathways, while the US office manages relationships with North American portfolio companies.
General information
Firm type
Multi Family Office
Year founded
2005
AUM
$500M - $1B (Altss estimate)
Location
Region
North America
Country
United States
City
West Palm Beach
Corporate office
West Palm Beach, FL, United States
Additional offices
Xiamen, China · Shanghai, China
Principals
not publicly disclosed
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs Sinobioway Medicine?
The CEO is not publicly disclosed, but the firm is led by a team of investment professionals with backgrounds in pharmaceuticals and venture capital across the US and China. The firm maintains a lean operating structure.
What investment stages does Sinobioway Medicine target?
Sinobioway Medicine invests from series A through growth equity, focusing on early-stage and scaling life sciences companies. It participates in direct investments and co-investments alongside institutional partners.
Does Sinobioway Medicine invest in fund commitments or only direct deals?
The firm primarily executes direct deals in healthcare technology and life sciences. It has been known to co-invest with other family offices and institutional investors on specific portfolio companies.
Which sectors does Sinobioway Medicine explicitly avoid?
The firm focuses exclusively on healthcare and life sciences — it does not invest in real estate, energy, or consumer technology outside of health-related applications.
How is Sinobioway Medicine structured?
Sinobioway Medicine operates as a multi-family office and asset manager, with offices in West Palm Beach, Xiamen, and Shanghai. The structure supports deal sourcing across both the US and Chinese healthcare markets.
Where does Sinobioway Medicine's underlying wealth come from?
The wealth originates from the pharmaceutical and life sciences industry, based on the firm's name and investment focus (Altss estimate). Specific family branches are not publicly disclosed.
Does Sinobioway Medicine maintain philanthropic structures?
The firm maintains separate philanthropic vehicles focused on global health access, though the specific structures and endowment sizes are not publicly detailed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: